Mineralys Therapeutics, Inc. (NASDAQ:MLYS) appears in 218 institutional 13F filings for the quarter ending December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| Catalys Pacific, LLC | 31 Mar, 2026 | 7,903,838 | 7,903,838 | 0.00% | $214,114,971.00 |
| RA CAPITAL MANAGEMENT, L.P. | 31 Mar, 2026 | 7,692,750 | 369,000 | 5.04% | $208,396,598.00 |
| RA CAPITAL MANAGEMENT, L.P. | 31 Mar, 2026 | 7,323,750 | 0 | 0.00% | $265,778,888.00 |
| Samsara BioCapital, LLC | 31 Mar, 2026 | 5,871,018 | 0 | 0.00% | $159,045,878.00 |
| Samsara BioCapital, LLC | 31 Mar, 2026 | 5,871,018 | -392,133 | -6.26% | $213,059,243.00 |
| FMR LLC | 31 Mar, 2026 | 5,057,509 | 2,986,254 | 144.18% | $183,537,002.00 |
| FMR LLC | 31 Mar, 2026 | 4,861,104 | -196,405 | -3.88% | $131,687,318.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 4,481,582 | 153,904 | 3.56% | $121,406,057.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 4,327,678 | 656,064 | 17.87% | $157,051,434.00 |
| Laurion Capital Management LP | 31 Mar, 2026 | 3,426,970 | 1,706,525 | 99.19% | $124,364,742.00 |
| WELLINGTON MANAGEMENT GROUP LLP | 31 Mar, 2026 | 3,359,068 | 2,574,801 | 328.31% | $90,997,151.00 |
| VANGUARD GROUP INC | 31 Mar, 2026 | 3,352,880 | 333,881 | 11.06% | $121,676,015.00 |
| State Street Corp | 31 Mar, 2026 | 3,184,999 | 1,881,976 | 144.43% | $115,583,614.00 |
| State Street Corp | 31 Mar, 2026 | 2,935,940 | -249,059 | -7.82% | $79,534,615.00 |
| Goldman Sachs Group Inc | 31 Mar, 2026 | 2,901,866 | 2,190,205 | 307.76% | $105,308,718.00 |
| Caligan Partners LP | 31 Mar, 2026 | 2,772,654 | 0 | 0.00% | $100,619,614.00 |
| Caligan Partners LP | 31 Mar, 2026 | 2,772,654 | 0 | 0.00% | $75,111,197.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 2,454,363 | 2,454,363 | 0.00% | $66,488,694.00 |
| Laurion Capital Management LP | 31 Mar, 2026 | 2,232,040 | -1,194,930 | -34.87% | $60,465,964.00 |
| ORBIMED ADVISORS LLC | 31 Mar, 2026 | 2,052,900 | 1,072,500 | 109.39% | $55,613,061.00 |